Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 352 entries
Sorted by: Best Match Show Resources per page
Assimilating online technologies into school culture

Science teachers

Dayan J, Kali Y, Shamir-Inbal T.
GSID: aHTB_QxCthIJ
T Shamir-Inbal, J Dayan, Y Kali - Interdisciplinary Journal of E …, 2009 - learntechlib.org

The goal of this research was to design, implement, and evaluate a three-year Teacher Professional Development (TPD) model with a socio-constructivist approach, intended to …

Cite
Shamir-Inbal, T., Dayan, J., & Kali, Y. (2009). Assimilating online technologies into school culture. Interdisciplinary Journal of E-Learning and Learning Objects, 5(1), 307-334.
Shamir-Inbal, Tamar, Jacob Dayan, and Yael Kali. "Assimilating online technologies into school culture." Interdisciplinary Journal of E-Learning and Learning Objects 5.1 (2009): 307-334.
Copy Download .nbib Format: MLA
Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease.

Clinical kidney journal

Vega A, Abad S, Macías N, Aragoncillo I, Santos A, Galán I, Cedeño S, Manuel López-Gómez J.
PMID: 28396734
Clin Kidney J. 2017 Apr;10(2):170-175. doi: 10.1093/ckj/sfw126. Epub 2017 Feb 08.

No abstract available.

Cite
Vega A, Abad S, Macías N, et al. Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease. Clin Kidney J. 2017;10(2):170-175doi: 10.1093/ckj/sfw126.
Vega, A., Abad, S., Macías, N., Aragoncillo, I., Santos, A., Galán, I., Cedeño, S., & Manuel López-Gómez, J. (2017). Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease. Clinical kidney journal, 10(2), 170-175. https://doi.org/10.1093/ckj/sfw126
Vega, Almudena, et al. "Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease." Clinical kidney journal vol. 10,2 (2017): 170-175. doi: https://doi.org/10.1093/ckj/sfw126
Vega A, Abad S, Macías N, Aragoncillo I, Santos A, Galán I, Cedeño S, Manuel López-Gómez J. Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease. Clin Kidney J. 2017 Apr;10(2):170-175. doi: 10.1093/ckj/sfw126. Epub 2017 Feb 08. PMID: 28396734; PMCID: PMC5381238.
Copy Download .nbib Format: NLM
Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM.

Epidemiology and infection

Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos LL, DE Serres G.
PMID: 25115531
Epidemiol Infect. 2015 Apr;143(6):1332. doi: 10.1017/S0950268814002088. Epub 2014 Aug 13.

No abstract available.

Cite
Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM. Epidemiol Infect. 2014;143(6):1332doi: 10.1017/S0950268814002088.
Brisson, M., Edmunds, W. J., Law, B., Gay, N. J., Walld, R., Brownell, M., Roos, L. L., & DE Serres, G. (2015). Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM. Epidemiology and infection, 143(6), 1332. https://doi.org/10.1017/S0950268814002088
Brisson, M, et al. "Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM." Epidemiology and infection vol. 143,6 (2015): 1332. doi: https://doi.org/10.1017/S0950268814002088
Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos LL, DE Serres G. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM. Epidemiol Infect. 2015 Apr;143(6):1332. doi: 10.1017/S0950268814002088. Epub 2014 Aug 13. PMID: 25115531.
Copy Download .nbib Format: NLM
Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Cite
Bloy N, Buqué A, Aranda F, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531doi: 10.1080/2162402X.2015.1026531.
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 4(5), e1026531. https://doi.org/10.1080/2162402X.2015.1026531
Bloy, Norma, et al. "Trial watch: Naked and vectored DNA-based anticancer vaccines." Oncoimmunology vol. 4,5 (2015): e1026531. doi: https://doi.org/10.1080/2162402X.2015.1026531
Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. PMID: 26155408; PMCID: PMC4485755.
Copy Download .nbib Format: NLM
Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease.

JAMA neurology

Lehallier B, Essioux L, Gayan J, Alexandridis R, Nikolcheva T, Wyss-Coray T, Britschgi M.
PMID: 26659895
JAMA Neurol. 2016 Feb;73(2):203-212. doi: 10.1001/jamaneurol.2015.3135. Epub 2015 Dec 14.

IMPORTANCE: A reliable method of detecting Alzheimer disease (AD) in its prodromal state is needed for patient stratification in clinical trials or for personalizing existing or potential upcoming therapies. Current cerebrospinal fluid (CSF)- or imaging-based single biomarkers for AD...

Cite
Lehallier B, Essioux L, Gayan J, et al. Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease. JAMA Neurol. 2015;73(2):203-212doi: 10.1001/jamaneurol.2015.3135.
Lehallier, B., Essioux, L., Gayan, J., Alexandridis, R., Nikolcheva, T., Wyss-Coray, T., Britschgi, M. (2016). Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease. JAMA neurology, 73(2), 203-212. https://doi.org/10.1001/jamaneurol.2015.3135
Lehallier, Benoit, et al. "Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease." JAMA neurology vol. 73,2 (2016): 203-212. doi: https://doi.org/10.1001/jamaneurol.2015.3135
Lehallier B, Essioux L, Gayan J, Alexandridis R, Nikolcheva T, Wyss-Coray T, Britschgi M. Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease. JAMA Neurol. 2016 Feb;73(2):203-212. doi: 10.1001/jamaneurol.2015.3135. Epub 2015 Dec 14. PMID: 26659895; PMCID: PMC5214993.
Copy Download .nbib Format: NLM
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
Influence of dimethyl dicarbonate on the resistance of Escherichia coli to a combined UV-Heat treatment in apple juice.

Frontiers in microbiology

Gouma M, Gayán E, Raso J, Condón S, Álvarez I.
PMID: 26042117
Front Microbiol. 2015 May 19;6:501. doi: 10.3389/fmicb.2015.00501. eCollection 2015.

Commercial apple juice inoculated with Escherichia coli was treated with UV-C, heat (55°C) and dimethyl dicarbonate - DMDC (25, 50, and 75 mg/L)-, applied separately and in combination, in order to investigate the possibility of synergistic lethal effects. The...

Cite
Gouma M, Gayán E, Raso J, et al. Influence of dimethyl dicarbonate on the resistance of Escherichia coli to a combined UV-Heat treatment in apple juice. Front Microbiol. 2015;6:501doi: 10.3389/fmicb.2015.00501.
Gouma, M., Gayán, E., Raso, J., Condón, S., & Álvarez, I. (2015). Influence of dimethyl dicarbonate on the resistance of Escherichia coli to a combined UV-Heat treatment in apple juice. Frontiers in microbiology, 6501. https://doi.org/10.3389/fmicb.2015.00501
Gouma, Maria, et al. "Influence of dimethyl dicarbonate on the resistance of Escherichia coli to a combined UV-Heat treatment in apple juice." Frontiers in microbiology vol. 6 (2015): 501. doi: https://doi.org/10.3389/fmicb.2015.00501
Gouma M, Gayán E, Raso J, Condón S, Álvarez I. Influence of dimethyl dicarbonate on the resistance of Escherichia coli to a combined UV-Heat treatment in apple juice. Front Microbiol. 2015 May 19;6:501. doi: 10.3389/fmicb.2015.00501. eCollection 2015. PMID: 26042117; PMCID: PMC4436884.
Copy Download .nbib Format: NLM
Solid lipid nanoparticles from amphiphilic calixpyrroles.

Journal of colloid and interface science

Helttunen K, Galán A, Ballester P, Bergenholtz J, Nissinen M.
PMID: 26609923
J Colloid Interface Sci. 2016 Feb 15;464:59-65. doi: 10.1016/j.jcis.2015.11.012. Epub 2015 Nov 10.

HYPOTHESIS: Macrocyclic amphiphiles form interesting self-assembling structures, including solid lipid nanoparticles, which have potential applications in drug encapsulation. Aryl-extended calixpyrroles, which act as anion binding hosts, are expected to form solid lipid nanoparticles, even though the alkyl chains have...

Cite
Helttunen K, Galán A, Ballester P, et al. Solid lipid nanoparticles from amphiphilic calixpyrroles. J Colloid Interface Sci. 2015;464:59-65doi: 10.1016/j.jcis.2015.11.012.
Helttunen, K., Galán, A., Ballester, P., Bergenholtz, J., & Nissinen, M. (2016). Solid lipid nanoparticles from amphiphilic calixpyrroles. Journal of colloid and interface science, 46459-65. https://doi.org/10.1016/j.jcis.2015.11.012
Helttunen, Kaisa, et al. "Solid lipid nanoparticles from amphiphilic calixpyrroles." Journal of colloid and interface science vol. 464 (2016): 59-65. doi: https://doi.org/10.1016/j.jcis.2015.11.012
Helttunen K, Galán A, Ballester P, Bergenholtz J, Nissinen M. Solid lipid nanoparticles from amphiphilic calixpyrroles. J Colloid Interface Sci. 2016 Feb 15;464:59-65. doi: 10.1016/j.jcis.2015.11.012. Epub 2015 Nov 10. PMID: 26609923.
Copy Download .nbib Format: NLM
Trial watch: Dendritic cell-based anticancer therapy.

Oncoimmunology

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25941593
Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov.

The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell...

Cite
Bloy N, Pol J, Aranda F, et al. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014;3(11):e963424doi: 10.4161/21624011.2014.963424.
Bloy, N., Pol, J., Aranda, F., Eggermont, A., Cremer, I., Fridman, W. H., Fučíková, J., Galon, J., Tartour, E., Spisek, R., Dhodapkar, M. V., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology, 3(11), e963424. https://doi.org/10.4161/21624011.2014.963424
Bloy, Norma, et al. "Trial watch: Dendritic cell-based anticancer therapy." Oncoimmunology vol. 3,11 (2014): e963424. doi: https://doi.org/10.4161/21624011.2014.963424
Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov. PMID: 25941593; PMCID: PMC4292311.
Copy Download .nbib Format: NLM
Next-generation sequencing to guide cancer therapy.

Genome medicine

Gagan J, Van Allen EM.
PMID: 26221189
Genome Med. 2015 Jul 29;7(1):80. doi: 10.1186/s13073-015-0203-x. eCollection 2015.

As a result of multiple technological and practical advances, high-throughput sequencing, known more commonly as "next-generation" sequencing (NGS), can now be incorporated into standard clinical practice. Whereas early protocols relied on samples that were harvested outside of typical clinical...

Cite
Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med. 2015;7(1):80doi: 10.1186/s13073-015-0203-x.
Gagan, J., & Van Allen, E. M. (2015). Next-generation sequencing to guide cancer therapy. Genome medicine, 7(1), 80. https://doi.org/10.1186/s13073-015-0203-x
Gagan, Jeffrey, and Van Allen, Eliezer M. "Next-generation sequencing to guide cancer therapy." Genome medicine vol. 7,1 (2015): 80. doi: https://doi.org/10.1186/s13073-015-0203-x
Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med. 2015 Jul 29;7(1):80. doi: 10.1186/s13073-015-0203-x. eCollection 2015. PMID: 26221189; PMCID: PMC4517547.
Copy Download .nbib Format: NLM
Mitochondrial Myopathy in Follow-up of a Patient With Chronic Fatigue Syndrome.

Journal of investigative medicine high impact case reports

Galán F, de Lavera I, Cotán D, Sánchez-Alcázar JA.
PMID: 26904705
J Investig Med High Impact Case Rep. 2015 Sep 24;3(3):2324709615607908. doi: 10.1177/2324709615607908. eCollection 2015.

Introduction. Symptoms of mitochondrial diseases and chronic fatigue syndrome (CFS) frequently overlap and can easily be mistaken. Methods. We report the case of a patient diagnosed with CFS and during follow-up was finally diagnosed with mitochondrial myopathy by histochemical...

Cite
Galán F, de Lavera I, Cotán D, et al. Mitochondrial Myopathy in Follow-up of a Patient With Chronic Fatigue Syndrome. J Investig Med High Impact Case Rep. 2015;3(3):2324709615607908doi: 10.1177/2324709615607908.
Galán, F., de Lavera, I., Cotán, D., & Sánchez-Alcázar, J. A. (2015). Mitochondrial Myopathy in Follow-up of a Patient With Chronic Fatigue Syndrome. Journal of investigative medicine high impact case reports, 3(3), 2324709615607908. https://doi.org/10.1177/2324709615607908
Galán, Fernando, et al. "Mitochondrial Myopathy in Follow-up of a Patient With Chronic Fatigue Syndrome." Journal of investigative medicine high impact case reports vol. 3,3 (2015): 2324709615607908. doi: https://doi.org/10.1177/2324709615607908
Galán F, de Lavera I, Cotán D, Sánchez-Alcázar JA. Mitochondrial Myopathy in Follow-up of a Patient With Chronic Fatigue Syndrome. J Investig Med High Impact Case Rep. 2015 Sep 24;3(3):2324709615607908. doi: 10.1177/2324709615607908. eCollection 2015. PMID: 26904705; PMCID: PMC4748504.
Copy Download .nbib Format: NLM
The immune landscape of human tumors: Implications for cancer immunotherapy.

Oncoimmunology

Bindea G, Mlecnik B, Angell HK, Galon J.
PMID: 24800163
Oncoimmunology. 2014 Jan 01;3(1):e27456. doi: 10.4161/onci.27456. Epub 2014 Jan 03.

Understanding the spontaneous immune response of cancer patients is critical for the design of efficient anticancer immunotherapies. The power of integrative tumor immunology approaches allowed for a comprehensive view of the immune system evolution in the course of tumor...

Cite
Bindea G, Mlecnik B, Angell HK, et al. The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology. 2014;3(1):e27456doi: 10.4161/onci.27456.
Bindea, G., Mlecnik, B., Angell, H. K., & Galon, J. (2014). The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology, 3(1), e27456. https://doi.org/10.4161/onci.27456
Bindea, Gabriela, et al. "The immune landscape of human tumors: Implications for cancer immunotherapy." Oncoimmunology vol. 3,1 (2014): e27456. doi: https://doi.org/10.4161/onci.27456
Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology. 2014 Jan 01;3(1):e27456. doi: 10.4161/onci.27456. Epub 2014 Jan 03. PMID: 24800163; PMCID: PMC4006852.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 352 entries